Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This research study is studying a drug as a possible treatment for Bronchiolitis Obliterans
Syndrome (BOS) after having an Allogeneic Hematopoietic Cell Transplantation (HCT).